Adding to its already busy metabolic disease portfolio, Boehringer Ingelheim GMBH has sealed a collaboration and license agreement with Denmark-based Gubra ApS, to develop peptide compounds for obesity. Gubra stands to receive up to €250m in upfront and success-based development and commercialization milestone payments, although details of the split between upfront payments and milestones were not disclosed.
Boehringer has various candidates in late preclinical and early clinical stages that it believes address the high therapeutic need in...








